Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
Sponsor: Novartis Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Novartis Pharmaceuticals
Other Advanced Gastric Cancer trials with similar outcome
This PHASE2 trial investigates Advanced Gastric Cancer and is currently terminated or withdrawn. Novartis Pharmaceuticals leads this study, which shows 10 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bordeaux, France , Heilbronn, Germany , Houston, United States , Kashiwa, Japan , Lake Success, United States , Leuven, Belgium , Los Angeles, United States , Mannheim, Germany , Modena, Italy and 4 more locations